An interventional study of non-invasive hyperspectral retinoscopy and blood sample in Alzheimer Disease, Early Onset, Cognitive Impairment and Cognitive Decline, sponsored by Mantis Photonics AB. Status unknown at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Mantis Photonics AB · Not applicable, Interventional, and Diagnostic
Two devices will be tested in this research:
Worldwide, millions of people are affected by neurodegenerative diseases (e.g., Alzheimer's disease, dementia). Those diseases are having a tremendous socio-economic impact on our society. The cost associated with treating and caring for those diseases is enormous. Overwhelming evidence indicates how selective lifestyle changes (e.g., reducing exposure to known risk factors) can sometimes significantly decrease the probability of developing the disease or delay its onset. However, the diseases must be diagnosed early for them to be effective. There is a lack of accessible, inexpensive, and non-invasive practices that would allow for an early diagnosis of different diseases, even at the primary physician's office. Mantis Photonics and Blekinge Tekniska Högskola (Institustionen för Hälsa) aim to fill this urgent unmet medical need.
Strong indications of the possibility of classifying Alzheimer's status based on hyperspectral scans of the retina have been published by different researchers. These results were obtained based on images taken with hyperspectral cameras with a different working principle than the Mantis Photonics camera. The working principle of the Mantis Photonics camera allows making a hyperspectral retinoscopy with the same spectral range and comparable or better spectral resolution with a machine that is more modular and lower in cost. There is thus reason to hypothesize retinal scans taken with the Mantis Photonics camera can be used for the same classification task.
Previous studies on the automated tablet computer cognitive test CoGNIT have established validity, reliability and sensitivity for testing patients with Normal Pressure Hydrocephalus (NPH) . Recently feasibility of testing in Mild Cognitive Impairment (MCI) was affirmed (Behrens, Berglund, \& Anderberg, CoGNIT Automated Tablet Computer Cognitive Testing in Patients With Mild Cognitive Impairment: Feasibility Study, 2022). In NPH patients, CoGNIT was more sensitive to cognitive impairment at baseline and cognitive improvement after shunt surgery than the Mini-Mental State Examination (MMSE).
Blood tests for amyloid-β and other biomarkers related to Alzheimer's disease are being investigated for clinical practice, but the technique is not accepted as a standard test. Research has shown that renal function influences amyloid-β clearance from the body. Also, analytical errors influence test results. Therefore, one can question the influence of normal repeatability of the blood test result.
The aim of this investigation is the evaluation, (further) development and comparison of non-invasive techniques for the evaluation of patients suffering mild cognitive impairment, in particular, the Mantis Photonics hyperspectral camera with classification machine learning model in combination with the CoGNIT test of Dr Behrens (Blekinge Tekniska Högskola). These techniques will be compared to the result of cerebrospinal fluid analysis (CSF), the reference biological diagnostic technique for Alzheimer's disease.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 80 is above the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Mantis Photonics AB is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
On all subjects included in the study (see inclusion / exclusion criteria and informed consent) both procedures will be performed. The result of these procedures (retinal scan, result from cognitive test and blood sample) will be used to build diagnostic classification models.
Procedure: non-invasive hyperspectral retinoscopy · Procedure: blood sample · Diagnostic Test: Test of cognitive ability on tablet computer with CoGNIT software
The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
Also known as: eye-scan, fundus image (of the eye)
The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
Also known as: draw blood
The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
Also known as: CoGNIT test, Cognitive test, Mental ability test
Accuracy (Statistical metric) retinal image classification model
Performance metric of the retinal image classification model: model accuracy \[percent\]
Time frame: within 2 months after last patient procedure
Area under the Curve (statistical metrics) retinal image classification model
Performance metric of the retinal image classification model: Area under the Curve (AuC) \[0 \< AuC \< 1\]
Time frame: within 2 months after last patient procedure
Sensitivity (Statistical metric) retinal image classification model
Performance metrics of the retinal image classification model: Sensitivity \[percent\]
Time frame: within 2 months after last patient procedure
CoGNIT test diagnostic accuracy
Accuracy \[percent\] of diagnosis based on the CoGNIT test data
Time frame: within 2 months after last patient procedure
Accuracy: Metrics combination model
A combination model of both non-invasive techniques will be evaluated based on the same metrics as the single-technique model (see primary objectives) and evaluated based on the comparison of said metrics: accuracy \[percent\] for the optimal choice of threshold.
Time frame: within 3 months after last patient procedure
Area Under the Curve: Metrics combination model
A combination model of both non-invasive techniques will be evaluated based on the same metrics as the single-technique model (see primary objectives) and evaluated based on the comparison of said metrics: Area Under the Curve \[0\<AUC\<1\] for the optimal choice of threshold.
Time frame: within 3 months after last patient procedure
Sensitivity: Metrics combination model
A combination model of both non-invasive techniques will be evaluated based on the same metrics as the single-technique model (see primary objectives) and evaluated based on the comparison of said metrics: sensitivity \[percent\] for the optimal choice of threshold.
Time frame: within 3 months after last patient procedure
Non invasive test variability compared to reference
The variability \[relative and normalized: percent\] between the first and the second hyperspectral retinoscopy result will be compared to the variability between the blood analysis at the first and the second appointment \[relative and normalized: percent\]. The blood test variability will be used as a reference in this study.
Time frame: within 3 months after last patient procedure
Adverse effect
Measurement: Percentage \[percent\] of patients who report adverse effects such as transient 'imprint' of the flash or other adverse effects.
Time frame: Immediately after the retinoscopy procedure
Serious adverse effect
Occurence of serious adverse effects due to the procedure. Any patient who suffers serious harm due to the procedure is a study outcome and a study endpoint.
Time frame: Immediately after the retinoscopy procedure
Plan to share: No — No Individual Participant Data (IPD) sharing to third parties. Data of individual participants will be used for this study only.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mantis Photonics AB